Abstract:collected for each patient before biopsy. The study was approved by the Institutional Ethics Review Board at Huashan Hospital and written informed consent was completed for each patient. Because the Hologic PCA3 kit is not currently available in China, urine PCA3 RNA level was measured using an in-house qPCR method and its level was normalized by urine levels of PSA mRNA. PCA3 level was calculated using ∆Ct = CtPCA3 − CtPSA. 8 Twenty-nine PCa risk-associated SNPs discovered from GWAS and confirmed in the Chinese population (P < 0.05) were genotyped using MassARRAY iPLEX (Sequenom, Inc., CA, USA).9 A GRS was calculated for each subject based on their genotypes at these 29 SNPs and weighted by odd ratios of these SNPs derived from an external study.10 Association of PCa diagnosis with PCA3, GRS, and other clinical variables were tested using both univariate and multivariate analyses. Total PSA, PCA3, free to total PSA ratio, and GRS were log-transformed prior to statistical tests. The key demographic and clinical variables for the 99 patients in the cohort, as well as their association with PCa risk, are presented in Table 1. Based on univariate analysis, higher PCA3 (P = 0.0002), higher total PSA (P = 0.0002), higher GRS (P = 0.0008), lower free to total PSA ratio (P = 0.007), and smaller prostate volume (P = 0.0003) were each associated with increased risk for PCa. The performance for discriminating PCa from non-PCa, measured by area under the curve (AUC), was 0.73 for total PSA, 0.77 for PCA3, and 0.70 for GRS. We also examined in detail the added value of PCA3 and GRS to total PSA in discriminating prostate biopsy outcomes (Table 2). Compared to Model 1 with total PSA alone where AUC was 0.73, the AUC increased to 0.81 for Model 2 with total PSA and GRS (P = 0.05), and to 0.84 for Model 3 with total PSA and PCA3 (P = 0.01). The AUC for Model 4 with all three variables (total PSA, GRS and PCA3) was further increased to 0.86, although the improvement was not statistically significant over Model 2 (P = 0.08) or Model 3 (P = 0.34). When all six variables were considered together in a multivariate analysis, only three variables were independently associated with PCa risk from a multivariate analysis; total PSA (P = 0.001), prostate volume (P = 0.0001), and PCA3 (P = 0.027). The AUC of the best multivariate model for discriminating PCa from non-PCa was excellent at 0.94. Dear Editor, We report here the performance of prostate cancer antigen 3 (PCA3) and genetic risk score (GRS) in predicting prostate cancer (PCa) from the prostate biopsy. To the best of our knowledge, this is the first report of simultaneously evaluating these two biomarkers in the same study. The incidence of PCa has increased in China over the last two decades, likely due to a combination of factors such as increase in life expectancy, better detection method of PCa, and life style changes.1 PCa is typically diagnosed from the prostate biopsy in patients with elevated prostate specific antigen (PSA) levels. However, for moderately elevated PSA levels, its specificity for PCa is relatively low because other prostate disorders may also lead to elevated PSA levels.2 Therefore, additional biomarkers are needed to complement PSA to better identify patients that may benefit from prostate biopsy. Two recently proposed biomarkers of PCa are promising. The first is a urine biomarker (PCA3), a noncoding RNA that was first reported in 1991 to have higher expression in prostate tumors than normal or benign prostate tissue.3 Since then several studies found that it can also be detected in the urine after digital rectal exam (DRE).4,5 A urine PCA3 test for considering a repeat biopsy in men 50 years of age or older who have had one or more previous negative prostate biopsies by Hologic Gen-Probe was approved by the European Medicines Agency and the United States Food and Drug Administration in 2012. The second is GRS derived from multiple PCa risk-associated single nucleotide polymorphisms (SNPs) identified from genome-wide association studies (GWAS).6,7 Although each of these two biomarkers has been evaluated individually, the combined effect of these two biomarkers in predicting PCa from the prostate biopsy have not been reported. We assessed the joint effect of these two biomarkers in a biopsy cohort of the Chinese population. Subjects in this study were patients scheduled for needle prostate biopsy at Huashan Hospital, Shanghai, China during 2012 and 2013. Blood samples and post-DRE urine were LETTER TO THE EDITOR

AB189. Prevalence and risk factors of prostate cancer in Chinese men with PSA 4–10 ng/mL underwent TRUS-guided prostate biopsy: the utilization of PAMD score

Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4–10 Ng/ml Who Underwent TRUS-Guided Prostate Biopsy: the Utilization of PAMD Score

Optimizing Prostate Cancer Accumulating Model: Combined PI-RADS V2 with Prostate Specific Antigen and Its Derivative Data.

A multicenter retrospective study on evaluation of predicative factors for positive biopsy of prostate cancer in real-world setting

Percent Free Prostate-Specific Antigen for Prostate Cancer Diagnosis in Chinese Men with a PSA of 4.0–10.0 Ng/ml: Results from the Chinese Prostate Cancer Consortium

Development and External Multicenter Validation of Chinese Prostate Cancer Consortium Prostate Cancer Risk Calculator for Initial Prostate Biopsy.

Current status of prostate biopsy in Chinese Prostate Cancer Consortium member hospitals

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 Ng/ml.

The Potential of a Nomogram Combined PI-RADS V2.1 and Contrast-Enhanced Ultrasound (CEUS) to Reduce Unnecessary Biopsies in Prostate Cancer Diagnostics

Evaluation of PSA-age Volume Score in Predicting Prostate Cancer in Chinese Population

Prostate Cancer Antigen 3 and Genetic Risk Score As Markers for the Detection of Prostate Cancer in the Chinese Population.

The Detection of Clinically Significant Prostate Cancer in Chinese Biopsy Naïve Men. the Role of Mpmri and Targeted Biopsy and Risk Stratification Using PSA Density

Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China.

Developing a Follow-Up Strategy for Patients with PSA Ranging from 4 to 10 Ng/ml Via a New Model to Reduce Unnecessary Prostate Biopsies.

Combining Clinical Parameters and Multiparametric Magnetic Resonance Imaging to Stratify Biopsy-Naïve Men for an Optimum Diagnostic Strategy with Prostate-Specific Antigen 4 Ng Ml−1 to 10 Ng Ml−1

The Role of Prostate-Specific Antigen Density and Negative Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer for Biopsy-Naïve Men: Clinical Outcomes from a High-Volume Center in China.

Risk Assessment Models to Evaluate the Necessity of Prostate Biopsies in North Chinese Patients with 4-50 Ng/ml PSA

Prediction of Prostate Cancer from Prostate Biopsy in Chinese Men Using a Genetic Score Derived from 24 Prostate Cancer Risk-Associated SNPs

Outcomes and Trends of Prostate Biopsy for Prostate Cancer in Chinese Men from 2003 to 2011.

The Combined Effect of Polygenic Risk Score and Prostate Health Index in Chinese Men Undergoing Prostate Biopsy

Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts